Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 17, 2020

Russia to begin clinical trials of Covid-19 vaccine candidate

The Russian Defence Ministry and the Gamalei National Research Center for Epidemiology and Microbiology are set to begin clinical trials of a Covid-19 vaccine candidate developed in the country.

The Russian Defence Ministry and the Gamalei National Research Center for Epidemiology and Microbiology are set to begin clinical trials of a Covid-19 vaccine candidate developed in the country.

Currently, the partners are making final preparations for the studies and expect to commence vaccinations in the coming days.

One group of participants will initially receive the vaccine at the end of the two–week quarantine period. The aim is to assess the safety and tolerability of the vaccine components.

Both military and civilian personnel will be enrolled for the trial. The Russian Defence Ministry noted that the parameters for the sample of volunteers have been discussed with the Ministry of Health.

Based on the data from the first group of volunteers, the remaining participants will be successively vaccinated with the vaccine components. This part of the trial is intended to evaluate the vaccine’s effectiveness and development of antibodies against SARS-CoV-2.

Prior to the human trials, the vaccine was tested for its toxicity, safety, immunogenicity and effectiveness in large and small animals at the Russian Defence Ministry’s 48th Central research institute.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The Russian Defence Ministry said in a statement: “Every day, a set of necessary measures is carried out to monitor the main vital indicators of volunteers and study a number of special parameters.

“Blood tests for IgG and IgM antibodies, oropharyngeal smear for PCR diagnostics on Covid-19 are taken. All volunteers have a high degree of motivation, well-tolerated quarantine and preparation for the main phase of testing.”

Last month, ChemRar Group and The Russian Direct Investment Fund (RDIF) reported positive results from a multi-centre clinical trial of Favipiravir in patients hospitalised due to Covid-19.

Of the 40 patients treated with the drug, 60% tested negative for coronavirus following five days of treatment, two times higher compared to those on standard therapy.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU